Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Total Liabilities (2020 - 2025)

Rapid Micro Biosystems' Total Liabilities history spans 6 years, with the latest figure at $40.1 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 86.66% year-over-year to $40.1 million; the TTM value through Sep 2025 reached $40.1 million, up 86.66%, while the annual FY2024 figure was $22.8 million, 10.39% down from the prior year.
  • Total Liabilities for Q3 2025 was $40.1 million at Rapid Micro Biosystems, up from $21.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $151.0 million in Q1 2021 and bottomed at -$179.0 million in Q3 2022.
  • The 5-year median for Total Liabilities is $21.5 million (2024), against an average of $5.2 million.
  • The largest annual shift saw Total Liabilities crashed 1009.59% in 2022 before it soared 118.82% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $20.2 million in 2021, then soared by 31.17% to $26.5 million in 2022, then dropped by 3.84% to $25.5 million in 2023, then dropped by 10.39% to $22.8 million in 2024, then surged by 75.64% to $40.1 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Total Liabilities are $40.1 million (Q3 2025), $21.0 million (Q2 2025), and $19.9 million (Q1 2025).